他汀类药物在肝病防治中的应用

刘路; 韩涛; 周冷潇

doi:10.3969/j.issn.1001-5256.2017.05.041

他汀类药物在肝病防治中的应用

DOI: 10.3969/j.issn.1001-5256.2017.05.041

天津市第三中心医院肝内科

详细信息

中图分类号: R575
计量
- 文章访问数: 1955
- HTML全文浏览量: 16
- PDF下载量: 478
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Application of statins in prevention and treatment of liver diseases

Department of Hepatology, Tianjin Third Central Hospital

摘要

摘要:
他汀类药物作为重要的降脂药物被广泛应用,研究已证实他汀类药物对于肝病患者来说是安全的。近年来有关他汀类药物在多种肝病包括丙型肝炎、脂肪性肝病、肝硬化和肝细胞癌防治领域的研究日益增多。研究发现除降脂功能外,他汀类药物还具有多种功能,包括抗炎、调节免疫、抗增殖、抗氧化以及改善血管内皮功能、抑制血小板聚集等,其在肝病防治中的作用值得进一步研究和探讨。
- 肝疾病 /
- 羟甲基戊二酰基CoA还原酶抑制剂 /
- 综述
Abstract:
Statins are widely used as important lipid-lowering drugs, and studies have proven the safety of statins in patients with liver diseases.In recent years, there have been more and more studies on the effects of statins in the prevention and treatment of hepatitis C, fatty liver disease, liver cirrhosis, and hepatocellular carcinoma.Studies have shown that besides the lipid-lowering effect, statins also have various other effects, including anti-inflammatory effect, immune regulation, anti-proliferation, and antioxidant effect, and they can also improve vascular endothelial function and inhibit platelet aggregation.Their roles in the prevention and treatment of liver diseases await further research.
- liver diseases /
- hydroxymethylglutaryl-CoA reductase inhibitors /
- review

HTML全文

参考文献(45)

[1]SIRTORI CR.The pharmacology of statins[J].Pharmacologica Res, 2014, 88 (9) :3-11.

[2]KEYSER CE, KOEHLER EM, SCHOUTEN JN, et al.Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals[J].Dig Liver Dis, 2014, 46 (8) :720-725.

[3]YE J, WANG C, SUMPTER R, et al.Disruption of hepatitis C virus RNA replication through inhibition of hosprotein geranylgeranylation[J].Proc Natl Acad Sci USA, 2003, 100 (26) :15865-15870.

[4]COREY KE, KANE E, MUNROE C, et al.Hepatitis C virus infection and its clearance alter circulating lipids:implications for long-term follow-up[J].Hepatology, 2009, 50 (4) :103-107.

[5]ZHU Q, LI N, HAN Q, et al.Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C:a systematic review and meta-analysis[J].Antiviral Res, 2013, 98 (3) :373-379.

[6]KONDO C, ATSUKAWA M, TSUBOTA A, et al.An open-labe randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin[J].J Viral Hepat, 2012, 19 (9) :615-622.

[7]HARRISON SA, ROSSARO L, HU KQ, et al.Serum cholestero and statin use predict virological response to pegintereron and ribavirin therapy[J].Hepatology, 2010, 52 (3) :864-874.

[8]PRASHANT P, FADI R, OELURIND O.Sustained virologic response and other potential enotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases[J].Clin Res Hepato Gastroenterol, 2015, 39 (5) :555-565.

[9]MOHANTY A, TATE J, GARCIA-TSAO G.Statins are Associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J].Gastroenterology, 2016, 150 (2) :430-440.

[10]SIMON T, BONILLA H, YAN P, et al.Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV[J].Hepatology, 2016, 64 (1) :47-57.

[11]BADER T, KORBA B.Simvastatin potentiates the anti-hepatitis Bvirus activity of FDA-approved nucleoside analogue inhibitors in vitro[J].Antiviral Res, 2010, 86 (3) :241-245.

[12]TSAN YT, LEE CH, WANG JD, et al.Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection[J].J Clin Oncol, 2012, 30 (6) :623-630.

[13]CHEN CI, KUAN CF, FANG YA, et al.Cancer risk in HBV patients with statin and metformin use:a population-based cohor study[J].Medicine (Baltimore) , 2015, 94 (6) :e462.

[14]HUANG YW, LEE CL, YANG SS, et al.Statins Reduce the risk o cirrhosis and its decompensation in chronic hepatitis B patients:Anationwide cohort study[J].Am J Gastroenterol, 2016, 111 (7) :976-985.

[15]ALAEI-ANDABILI SH, ALAVIAN SM.Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis:a systematic review and meta-analysis[J].Vaccine, 2012, 30 (38) :5595-5602.

[16]OKETANI M, IDO A, NAKAYAMA N, et al.Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan:summary of the annual nationwide survey between 2004 and 2009[J].Hepato Res, 2013, 43 (2) :97-105.

[17]GODSTEN MR, MASCITELLI L, PEZZETTA F.The double-edged sword of statin immunomodulation[J].Int J Cardiol, 2009, 135 (1) :128-130.

[18]WU DC.Hepatitis B virus reactivation associated with atorvastatin[J].Int J Cardiol, 2013, 17 (11) :e1069-e1070.

[19]MARRONE G, MAESO-DIAZ R, GARCIA-CADENA G, et al.KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers:behind the molecular mechanisms of statins[J].Gut, 2015, 64 (9) :1434-1443.

[20]VILLA E, CAMMA C, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.

[21]ANSTEE QM, WRIGHT M, GOLDIN R, et al.Parenchymal extinction:coagulation and hepatic fibrogenesis[J].Clin Liver Dis, 2009, 13 (1) :117-126.

[22]LOTSCH F, KONIGSBRUGGE O, POSCH F, et al.Statins are associated with low risk of venous thromboembolism in patients with cancer:a prospective and observational cohort study[J].Thromb Res, 2014, 134 (5) :1008-1013.

[23]SAHEBKAR A, SERBAN C, URSONIU S, et al.The impact of statin therapy on plasma levels of von Willebrand factor antigen.Systematic review and meta-analysis of randomised placebo-controlled trials[J].Thromb Haemost, 2016, 115 (3) :520-532.

[24]RAY K.Liver:Sussing out statins in cirrhosis-KLF2 is the key[J].Nat Rev Gastroenterol Hepatol, 2015, 12 (2) :64.

[25]MOTZKUS-FEAGANS C, PAKYZ AL, RATLIFF SM, et al.Statin use and infections in veterans with cirrhosis[J].Aliment Pharmacol Ther, 2013, 38 (6) :611-618.

[26]JANDA S, YOUNG A, FITZGERALD JM, et al.The effect of statins on mortality from severe infections and sepsis:a systematic review and meta-analysis[J].J Crit Care, 2010, 25 (4) :656, e7-e22.

[27]PATEL JM, SNAITH C, THICKETT DR, et al.Randomized doubleblind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial) [J].J Crit Care, 2012, 16 (6) :r231.

[28]KUMAR S, GRACE ND, QAMAR AA.Statin use in patients with cirrhosis:a retrospective cohort study[J].Dig Dis Sci, 2014, 59 (8) :1958-1965.

[29]CABRERA L, ABRALDES JG.Statins:the panacea of cirrhosis?[J].Curr Hepatol Rep, 2016, 15 (1) :1-7.

[30]ZAFRA C, ABRALDES JG, TURNES J, et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J].Gastroenterology, 2004, 126 (3) :749-755.

[31]ABRALDER JG, ALBILLOS A, BANARES R, et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial[J].Gastroenterology, 2009, 136 (5) :1651-1658.

[32]ABRALDES JG, VILLANUEVAL C, ARACIL C, et al.Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J].Gastroenterology, 2016, 150 (5) :1160-1170.

[33]AKOFERL B, LEPENNEC V, CHICHE L, et al.Hepatocellular cancer in the non-cirrhotic liver[J].J Visc Surg, 2011, 148 (1) :3-11.

[34]SINGH S, SINGH PP, ROBERT LR, et al.Chemopreventive strategies in hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (1) :45-54.

[35]SINGH S, SINGH PP, SINGH AG, et al.Statins are associated with a reduced risk of hepatocellular cancer:a systematic review and meta-analysis[J].Gastroenterology, 2013, 144 (2) :323-332.

[36]HSIANG JC, WONG GL, TSE YK, et al.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population:a propensity score landmark analysis[J].JHepatol, 2015, 63 (5) :1190-1197.

[37]JEON CY, GOODMAN MT, COOK-WIENS G, et al.Statin use and survival with early-stage hepatocellular carcinoma[J].Cancer Epidemiol Biomarkers Prev, 2016, 25 (4) :686-692.

[38]KAWATA S, YAMASAKI E, NAGASE T, et al.Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.A randomized controlled trial[J].Br J Cancer, 2001, 84 (7) :886-891.

[39]GRAF H, JUNGST C, STRAUB G, et al.Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma[J].Digestion, 2008, 78 (1) :34-38.

[40]SHAO JY, LEE FP, CHANG CL, et al.Statin-based palliative therapy for hepatocellular carcinoma[J].Medicine (Baltimore) , 2015, 94 (42) :e1801.

[41]CASH WJ, O’NEILL S, O’DONNELL ME, et al.Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis[J].Liver Int, 2013, 33 (8) :1-9.

[42]BAYS H, COHEN DE, CHALASANI N, et al.An assessment by the statin liver safety task force:2014 up-date[J].J Clin Lipidol, 2014, 8 (3) :s47-s57.

[43]TIKKANT MJ, FAYYAD R, PAERGEMAN O, et al.Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels[J].Int J Cardiol, 2013, 168 (4) :3846-3852.

[44]LEWIS JH, MORTENSEN ME, ZWEIG S, et al.Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease:results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial[J].Hepatology, 2007, 46 (5) :1453-1463.

[45]FORSTER T, BUDOFF MJ, SAAB S, et al.Atorvastatin and ntioxidants for the treatment of nonalcoholic fatty liver disease:the St.Francis Heart Study random-ized clinical trial[J].Am J Gastroenterol, 2011, 106 (1) :71-77.

施引文献

资源附件(0)

访问统计